Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Imaging, Diagnosis, Prognosis

ColoGuidePro: A Prognostic 7-Gene Expression Signature for Stage III Colorectal Cancer Patients

Anita Sveen, Trude H. Ågesen, Arild Nesbakken, Gunn Iren Meling, Torleiv O. Rognum, Knut Liestøl, Rolf I. Skotheim and Ragnhild A. Lothe
Anita Sveen
1Department of Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital, 2Department of Gastrointestinal Surgery, Aker University Hospital, Oslo University Hospital; 3Centre for Cancer Biomedicine, Faculty of Medicine, 4Department of Informatics, University of Oslo; 5Department of Forensic Pathology And Clinical Forensic Medicine, Division for Forensic Medicine, The Norwegian Institute of Public Health, Oslo; and 6Akershus University Hospital, University of Oslo, Research Centre, Lørenskog, Norway
1Department of Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital, 2Department of Gastrointestinal Surgery, Aker University Hospital, Oslo University Hospital; 3Centre for Cancer Biomedicine, Faculty of Medicine, 4Department of Informatics, University of Oslo; 5Department of Forensic Pathology And Clinical Forensic Medicine, Division for Forensic Medicine, The Norwegian Institute of Public Health, Oslo; and 6Akershus University Hospital, University of Oslo, Research Centre, Lørenskog, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trude H. Ågesen
1Department of Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital, 2Department of Gastrointestinal Surgery, Aker University Hospital, Oslo University Hospital; 3Centre for Cancer Biomedicine, Faculty of Medicine, 4Department of Informatics, University of Oslo; 5Department of Forensic Pathology And Clinical Forensic Medicine, Division for Forensic Medicine, The Norwegian Institute of Public Health, Oslo; and 6Akershus University Hospital, University of Oslo, Research Centre, Lørenskog, Norway
1Department of Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital, 2Department of Gastrointestinal Surgery, Aker University Hospital, Oslo University Hospital; 3Centre for Cancer Biomedicine, Faculty of Medicine, 4Department of Informatics, University of Oslo; 5Department of Forensic Pathology And Clinical Forensic Medicine, Division for Forensic Medicine, The Norwegian Institute of Public Health, Oslo; and 6Akershus University Hospital, University of Oslo, Research Centre, Lørenskog, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arild Nesbakken
1Department of Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital, 2Department of Gastrointestinal Surgery, Aker University Hospital, Oslo University Hospital; 3Centre for Cancer Biomedicine, Faculty of Medicine, 4Department of Informatics, University of Oslo; 5Department of Forensic Pathology And Clinical Forensic Medicine, Division for Forensic Medicine, The Norwegian Institute of Public Health, Oslo; and 6Akershus University Hospital, University of Oslo, Research Centre, Lørenskog, Norway
1Department of Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital, 2Department of Gastrointestinal Surgery, Aker University Hospital, Oslo University Hospital; 3Centre for Cancer Biomedicine, Faculty of Medicine, 4Department of Informatics, University of Oslo; 5Department of Forensic Pathology And Clinical Forensic Medicine, Division for Forensic Medicine, The Norwegian Institute of Public Health, Oslo; and 6Akershus University Hospital, University of Oslo, Research Centre, Lørenskog, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gunn Iren Meling
1Department of Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital, 2Department of Gastrointestinal Surgery, Aker University Hospital, Oslo University Hospital; 3Centre for Cancer Biomedicine, Faculty of Medicine, 4Department of Informatics, University of Oslo; 5Department of Forensic Pathology And Clinical Forensic Medicine, Division for Forensic Medicine, The Norwegian Institute of Public Health, Oslo; and 6Akershus University Hospital, University of Oslo, Research Centre, Lørenskog, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Torleiv O. Rognum
1Department of Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital, 2Department of Gastrointestinal Surgery, Aker University Hospital, Oslo University Hospital; 3Centre for Cancer Biomedicine, Faculty of Medicine, 4Department of Informatics, University of Oslo; 5Department of Forensic Pathology And Clinical Forensic Medicine, Division for Forensic Medicine, The Norwegian Institute of Public Health, Oslo; and 6Akershus University Hospital, University of Oslo, Research Centre, Lørenskog, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Knut Liestøl
1Department of Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital, 2Department of Gastrointestinal Surgery, Aker University Hospital, Oslo University Hospital; 3Centre for Cancer Biomedicine, Faculty of Medicine, 4Department of Informatics, University of Oslo; 5Department of Forensic Pathology And Clinical Forensic Medicine, Division for Forensic Medicine, The Norwegian Institute of Public Health, Oslo; and 6Akershus University Hospital, University of Oslo, Research Centre, Lørenskog, Norway
1Department of Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital, 2Department of Gastrointestinal Surgery, Aker University Hospital, Oslo University Hospital; 3Centre for Cancer Biomedicine, Faculty of Medicine, 4Department of Informatics, University of Oslo; 5Department of Forensic Pathology And Clinical Forensic Medicine, Division for Forensic Medicine, The Norwegian Institute of Public Health, Oslo; and 6Akershus University Hospital, University of Oslo, Research Centre, Lørenskog, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rolf I. Skotheim
1Department of Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital, 2Department of Gastrointestinal Surgery, Aker University Hospital, Oslo University Hospital; 3Centre for Cancer Biomedicine, Faculty of Medicine, 4Department of Informatics, University of Oslo; 5Department of Forensic Pathology And Clinical Forensic Medicine, Division for Forensic Medicine, The Norwegian Institute of Public Health, Oslo; and 6Akershus University Hospital, University of Oslo, Research Centre, Lørenskog, Norway
1Department of Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital, 2Department of Gastrointestinal Surgery, Aker University Hospital, Oslo University Hospital; 3Centre for Cancer Biomedicine, Faculty of Medicine, 4Department of Informatics, University of Oslo; 5Department of Forensic Pathology And Clinical Forensic Medicine, Division for Forensic Medicine, The Norwegian Institute of Public Health, Oslo; and 6Akershus University Hospital, University of Oslo, Research Centre, Lørenskog, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ragnhild A. Lothe
1Department of Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital, 2Department of Gastrointestinal Surgery, Aker University Hospital, Oslo University Hospital; 3Centre for Cancer Biomedicine, Faculty of Medicine, 4Department of Informatics, University of Oslo; 5Department of Forensic Pathology And Clinical Forensic Medicine, Division for Forensic Medicine, The Norwegian Institute of Public Health, Oslo; and 6Akershus University Hospital, University of Oslo, Research Centre, Lørenskog, Norway
1Department of Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital, 2Department of Gastrointestinal Surgery, Aker University Hospital, Oslo University Hospital; 3Centre for Cancer Biomedicine, Faculty of Medicine, 4Department of Informatics, University of Oslo; 5Department of Forensic Pathology And Clinical Forensic Medicine, Division for Forensic Medicine, The Norwegian Institute of Public Health, Oslo; and 6Akershus University Hospital, University of Oslo, Research Centre, Lørenskog, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-11-3302 Published November 2012
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: Improved prognostic stratification of patients with stage II and III colorectal cancer is warranted for postoperative clinical decision making. This study was conducted to develop a clinically feasible and robust prognostic classifier for these patients independent of adjuvant treatment.

Experimental Design: Global gene expression profiles from altogether 387 stage II and III colorectal cancer tissue samples from three independent patient series were included in the study. ColoGuidePro, a seven-gene prognostic classifier, was developed from a selected Norwegian learning series (n = 95; no adjuvant treatment) using lasso-penalized multivariate survival modeling with cross-validation.

Results: The expression signature significantly stratified patients in a consecutive Norwegian test series, in which patients were treated according to current standards [HR, 2.9 (1.1–7.5); P = 0.03; n = 77] and an external validation series [HR, 3.7 (2.0–6.8); P < 0.001; n = 215] according to survival. ColoGuidePro was also an independent predictor of prognosis in multivariate models including tumor stage in both series (HR, ≥3.1; P ≤ 0.03). In the validation series, which consisted of patients from other populations (United States and Australia), 5-year relapse-free survival was significantly predicted for stage III patients only (P < 0.001; n = 107). Here, prognostic stratification was independent of adjuvant treatment (P = 0.001).

Conclusions: We present ColoGuidePro, a prognostic classifier developed for patients with stage II and III colorectal cancer. The test is suitable for transfer to clinical use and has best prognostic prediction potential for stage III patients. Clin Cancer Res; 18(21); 6001–10. ©2012 AACR.

Footnotes

  • Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

  • Received December 22, 2011.
  • Revision received August 15, 2012.
  • Accepted August 28, 2012.
  • ©2012 American Association for Cancer Research.
View Full Text
PreviousNext
Back to top
Clinical Cancer Research: 18 (21)
November 2012
Volume 18, Issue 21
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
ColoGuidePro: A Prognostic 7-Gene Expression Signature for Stage III Colorectal Cancer Patients
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
ColoGuidePro: A Prognostic 7-Gene Expression Signature for Stage III Colorectal Cancer Patients
Anita Sveen, Trude H. Ågesen, Arild Nesbakken, Gunn Iren Meling, Torleiv O. Rognum, Knut Liestøl, Rolf I. Skotheim and Ragnhild A. Lothe
Clin Cancer Res November 1 2012 (18) (21) 6001-6010; DOI: 10.1158/1078-0432.CCR-11-3302

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
ColoGuidePro: A Prognostic 7-Gene Expression Signature for Stage III Colorectal Cancer Patients
Anita Sveen, Trude H. Ågesen, Arild Nesbakken, Gunn Iren Meling, Torleiv O. Rognum, Knut Liestøl, Rolf I. Skotheim and Ragnhild A. Lothe
Clin Cancer Res November 1 2012 (18) (21) 6001-6010; DOI: 10.1158/1078-0432.CCR-11-3302
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • FDOPA PET Survival Predictions for Glioma
  • In vivo Fluorescence Lifetime Imaging for Monitoring the Cancer Treatment
  • Variability in Assessing Response in Metastatic Colorectal Cancer
Show more Imaging, Diagnosis, Prognosis
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement